Literature DB >> 15039281

A report from the LALA-94 and LALA-SA groups on hypodiploidy with 30 to 39 chromosomes and near-triploidy: 2 possible expressions of a sole entity conferring poor prognosis in adult acute lymphoblastic leukemia (ALL).

Christiane Charrin1, Xavier Thomas, Martine Ffrench, Quoc-Hung Le, Joris Andrieux, Marie-Joelle Mozziconacci, Jean-Luc Laï, Chrystele Bilhou-Nabera, Lucienne Michaux, Alain Bernheim, Christian Bastard, Hossein Mossafa, Christine Perot, Odile Maarek, Claude Boucheix, Véronique Lheritier, André Delannoy, Denis Fière, Nicole Dastugue.   

Abstract

To reveal the relationship between hypodiploidy with 30 to 39 chromosomes and near-triploidy in acute lymphoblastic leukemia (ALL), we studied 24 patients presenting with one of these aneuploidies among 623 adults with ALL registered in the Leucemie Aigue Lymphoblastique de l'Adulte (LALA) protocols. The 2 ploidy groups presented a striking similarity of their cytogenetic profiles: chromosomes 2, 3, 4, 7, 13, 15, 16, and 17, significantly monosomic in hypodiploidy 30 to 39, were also frequently disomic in near-triploidy, whereas those retained in pairs in hypodiploidy 30 to 39 were frequently tetrasomic in near-triploidy. DNA content data revealed the simultaneous presence of 2 aneuploid peaks in most tested cases (DNA indexes: 0.72-0.87/1.39-1.89) and a multiple correspondence analysis applied on cytogenetic profiles ascertained their strong relationship. We thus assumed that near-triploidy derives from the duplication of hypodiploidy with 30 to 39 chromosomes and that both aneuploid groups are 2 expressions of the same disease. These 24 patients presented with B-cell phenotype, low leukocytoses (median white blood cell count, 4.2 x 10(9)/L), and poor prognosis (complete remission, 57%; median disease-free-survival, 8 months; median survival, 10.4 months) comparable to that of Ph(+) patients treated according to the same protocol. We suggest that hypodiploidy with 30 to 39 chromosomes or near-triploidy should be regarded as a new high-risk factor in the risk stratification of adult ALL protocols.

Entities:  

Mesh:

Year:  2004        PMID: 15039281     DOI: 10.1182/blood-2003-04-1299

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Array-based comparative genomic hybridization detects copy number variations with prognostic relevance in 80% of ALL with normal karyotype or failed chromosome analysis.

Authors:  V Mühlbacher; T Haferlach; W Kern; M Zenger; S Schnittger; C Haferlach
Journal:  Leukemia       Date:  2015-10-09       Impact factor: 11.528

2.  Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group.

Authors:  Andrew J Carroll; Mary Shago; Fady M Mikhail; Susana C Raimondi; Betsy A Hirsch; Mignon L Loh; Elizabeth A Raetz; Michael J Borowitz; Brent L Wood; Kelly W Maloney; Leonard A Mattano; Eric C Larsen; Julie Gastier-Foster; Eileen Stonerock; Denise Ell; Samir Kahwash; Meenakshi Devidas; Richard C Harvey; I-Ming L Chen; Cheryl L Willman; Stephen P Hunger; Naomi J Winick; William L Carroll; Kathleen W Rao; Nyla A Heerema
Journal:  Cancer Genet       Date:  2019-07-30

3.  Novel gene targets detected by genomic profiling in a consecutive series of 126 adults with acute lymphoblastic leukemia.

Authors:  Setareh Safavi; Markus Hansson; Karin Karlsson; Andrea Biloglav; Bertil Johansson; Kajsa Paulsson
Journal:  Haematologica       Date:  2014-09-26       Impact factor: 9.941

Review 4.  How I treat acute lymphoblastic leukemia in older adolescents and young adults.

Authors:  Emily Curran; Wendy Stock
Journal:  Blood       Date:  2015-03-24       Impact factor: 22.113

Review 5.  Hematopoietic stem cell transplantation for leukemia.

Authors:  Alan S Wayne; Kristin Baird; R Maarten Egeler
Journal:  Pediatr Clin North Am       Date:  2010-02       Impact factor: 3.278

6.  Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group.

Authors:  Jennifer L McNeer; Meenakshi Devidas; Yunfeng Dai; Andrew J Carroll; Nyla A Heerema; Julie M Gastier-Foster; Samir B Kahwash; Michael J Borowitz; Brent L Wood; Eric Larsen; Kelly W Maloney; Leonard Mattano; Naomi J Winick; Kirk R Schultz; Stephen P Hunger; William L Carroll; Mignon L Loh; Elizabeth A Raetz
Journal:  J Clin Oncol       Date:  2019-02-11       Impact factor: 50.717

7.  Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.

Authors:  Ghayas C Issa; Hagop M Kantarjian; C Cameron Yin; Wei Qiao; Farhad Ravandi; Deborah Thomas; Nicholas J Short; Koji Sasaki; Guillermo Garcia-Manero; Tapan M Kadia; Jorge E Cortes; Naval Daver; Gautam Borthakur; Nitin Jain; Marina Konopleva; Issa Khouri; Partow Kebriaei; Richard E Champlin; Sherry Pierce; Susan M O'Brien; Elias Jabbour
Journal:  Cancer       Date:  2016-10-03       Impact factor: 6.860

8.  Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia.

Authors:  James B Nachman; Nyla A Heerema; Harland Sather; Bruce Camitta; Erik Forestier; Christine J Harrison; Nicole Dastugue; Martin Schrappe; Ching-Hon Pui; Giuseppe Basso; Lewis B Silverman; Gritta E Janka-Schaub
Journal:  Blood       Date:  2007-05-01       Impact factor: 22.113

9.  Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.

Authors:  Vinod Pullarkat; Marilyn L Slovak; Kenneth J Kopecky; Stephen J Forman; Frederick R Appelbaum
Journal:  Blood       Date:  2007-12-21       Impact factor: 22.113

10.  Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia.

Authors:  Ryan D Cassaday; D Alan Potts; Philip A Stevenson; Merav Bar; George E Georges; Andrei R Shustov; Mohamed L Sorror; Brent L Wood; Colleen Delaney; Kristine C Doney; Rainer F Storb; Brenda M Sandmaier
Journal:  Leuk Lymphoma       Date:  2016-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.